Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1533-1549

  Du, Huizhi ^a   Chen, Xiaolei ^a   Zhang, Jian ^a   Chen, Chu ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

cyclooxygenase 2; endocannabinoids; monoacylglycerol lipase; neuroinflammation; nuclear factor B; peroxisome proliferator activated receptor

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 CHLORO 5 NITROBENZANILIDE; ACYLGLYCEROL LIPASE; ANTIINFLAMMATORY AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; JZL 184; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN G2; ROSIGLITAZONE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; URB 602; 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; BETA ACTIN; CANNABINOID 1 RECEPTOR; ESTERASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG HYDROLYSIS; ENZYME INHIBITION; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; MINIATURE ENDPLATE POTENTIAL; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL TISSUE; DOWN REGULATION; DRUG MECHANISM; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; NERVE CELL CULTURE; NERVOUS SYSTEM INFLAMMATION; PROTEIN DETERMINATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; UPREGULATION; ENZYME ACTIVITY; SYNAPTIC TRANSMISSION;

ANILIDES; ANIMALS; ARACHIDONIC ACIDS; BENZODIOXOLES; BIPHENYL COMPOUNDS; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOCANNABINOIDS; EXCITATORY POSTSYNAPTIC POTENTIALS; GLYCERIDES; HIPPOCAMPUS; INFLAMMATION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICE; MONOACYLGLYCEROL LIPASES; NEURONS; NF-KAPPA B; PHOSPHORYLATION; PIPERIDINES; PPAR GAMMA; PROSTAGLANDIN D2; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; THIAZOLIDINEDIONES;

EID: 79960310251     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01444.x     Document Type: Article

References (71)

1. Akaneya Y, Tsumoto T, (2006). Bidirectional trafficking of prostaglandin E2 receptors involved in long-term potentiation in visual cortex. J Neurosci 26: 10209-10221. (Pubitemid 44527414)
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to receptors and channels (GRAC). 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Alger BE, (2002). Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68: 247-286. (Pubitemid 36009278)
4. Bensinger ST, Tontonoz P, (2008). Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454: 470-477.
5. Blankman JL, Simon GM, Cravavtt BF, (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonylglycerol. Chem Biol 14: 1347-1356. (Pubitemid 350257008)
6. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S, (2008). PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res 2008: 1-12.
7. Centonze D, Finazzi-Agro A, Bernardi G. Maccarrone M, (2007). The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28: 180-187. (Pubitemid 46483718)
8. Cernak I, Vink R, Natale J, Stoica B, Lea PM 4th, Movsesyan V, et al,. (2004). The 'dark side' of endocannabinoids: a neurotoxic role for anandamide. J Cereb Blood Flow Metab 24: 564-578. (Pubitemid 38608289)
9. Chen C, (2010). COX-2's new role in inflammation. Nat Chem Biol 6: 402-402.
10. Chen C, Bazan NG, (2005). Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J Neurophysiol 93: 929-941.
11. Chen C, Magee JC, Bazan NG, (2002). Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol 87: 2851-2857. (Pubitemid 34670665)
12. Chen X, Zhang J, Chen C, (2011). Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neurosci 178: 159-168.
13. Chevaleyre V, Takahashi KA, Castillo PE, (2006). Endocannabinoid-Mediated Synaptic Plasticity in the CNS. Ann Rev Neurosci 29: 37-76. (Pubitemid 44476839)
14. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B, (2007). The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 152: 787-794. (Pubitemid 350034978)
15. Daynes RA, Jones DC, (2002). Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748-759. (Pubitemid 37328715)
16. Drew PD, Xu J, Storer PD, Chavis JA, Racke MK, (2006). Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int 49: 183-189. (Pubitemid 43867076)
17. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, et al,. (2006). The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79. (Pubitemid 43017186)
18. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A, (2010). Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity? Exp Neurol 224: 37-47.
19. Freund TF, Katona I, Piomelli D, (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066. (Pubitemid 36828930)
20. Glass CK, Saijo K, Winner B, Marchetto MA, Gage FH, (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
21. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S, et al,. (2005). Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 56: 590-604.
22. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al,. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112. (Pubitemid 40910518)
23. Jiang C, Ting AT, Seed B, (1998). PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86. (Pubitemid 28079219)
24. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M, (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380.
25. King AR, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper JR, et al,. (2007). RB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol 14: 1357-1365. (Pubitemid 350257009)
26. Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, DuBois RN, et al,. (2002). 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 277: 23278-23286. (Pubitemid 34952156)
27. Kozak KR, Prusakiewicz JL, Marnett LJ, (2004). Oxidative metabolism of endocannabinoids by COX-2. Curr Pharmaceut Design 10: 659-667. (Pubitemid 38292392)
28. Kreutz S, Koch M, Ghadban C, Korf HW, Dehghani F, (2007). Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol 203: 246-257. (Pubitemid 44821182)
29. Lee G, Elwood F, McNally J, Weiszmann J, Lindstrom M, Amaral K, et al,. (2002). T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem 277: 19649-19657. (Pubitemid 34967479)
30. Lenman A, Fowler CJ, (2007). Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system. Br J Pharmacol 151: 1343-1351. (Pubitemid 47255913)
31. Long JZ, Normura DK, Cravatt BF, (2009a). Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
32. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al,. (2009b). Selective blockade of 2-arachidonoylglycerol hydrolysis producs cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
33. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Marti'nez A, Perez-Castillo A, (2005). Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferatoractivated receptor γ activation. J Biol Chem 280: 21453-21462. (Pubitemid 40805710)
34. Mackie K, (2006). Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101-122.
35. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, et al,. (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13: 951-957.
36. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al,. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88. (Pubitemid 37210691)
37. Melis M, Pillolla G, Bisogno T, Minassi A, Petrosino S, Perra S, et al,. (2006). Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis 24: 15-27. (Pubitemid 44416209)
38. Movsesyan VA, Stoica BA, Yakovlev AG, Knoblach SM, Lea PM 4th, Cernak I, et al,. (2004). Anandamide-induced cell death in primary neuronal cultures: role of calpain and caspase pathways. Cell Death Differ 11: 1121-1132. (Pubitemid 39341638)
39. Necela BM, Su W, Thomson EA, (2008). Toll-like receptor 4 mediates cross-talk between peroxisom proliferator-activated receptor γ and nuclear factor-κB in macrophages. Immunol 125: 344-358.
40. O'Sullivan SE, (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582. (Pubitemid 350034977)
41. O'Sullivan SE, Kendall DA, (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiol 215: 611-616.
42. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, et al,. (2009). Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl) piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 331: 591-597.
43. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al,. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 427-531.
44. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E, (2005). CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 25: 477-484.
45. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al,. (2006). The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22: 257-264.
46. Park EJ, Park SY, Joe EH, Jou I, (2003). 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 278: 14747-14752. (Pubitemid 36799798)
47. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al,. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
48. Piomelli D, (2003). The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 4: 873-884.
49. Pistis M, Melis M, (2010). From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem 17: 1450-1467.
50. Racke MK, Drew PD, (2008). PPARs in neuroinflammation. PPAR Res 2008: 638356.
51. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK, (1998). The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation. Nature 391: 79-82. (Pubitemid 28079218)
52. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE, (2006). Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70: 101-111.
53. Rockwell CE, Raman P, Kaplan BL, Kaminski NE, (2008). A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells. Biochem Pharmacol 76: 353-361.
54. Sang N, Chen C, (2006). Lipid signaling and synaptic plasticity. Neuroscientist 12: 425-434. (Pubitemid 44316321)
55. 2 EP2 receptor. J Neurosci 25: 9858-9870. (Pubitemid 41528023)
56. 2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol (Lond) 572: 735-745.
57. Sang N, Zhang J, Chen C, (2007). COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity. J Neurochem 103: 1966-1977. (Pubitemid 47329266)
58. Sang N, Zhang J, Chen C, (2010). Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. Neurochem Intl 56: 590-596.
59. Sarne Y, Mechoulam R, (2005). Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Target- CNS Neurol Dis 4: 677-684. (Pubitemid 41782629)
60. Sinha D, Bonner TI, Bhat NR, Matsuda LA, (1998). Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. J Neuroimmunol 82: 13-21. (Pubitemid 28129331)
61. Slanina KA, Schweitzer P, (2005). Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus. Neuropharmacol 49: 653-659. (Pubitemid 41208287)
62. Stella N, (2004). Cannabinoid signaling in glial cells. Glia 48: 267-277. (Pubitemid 39578029)
63. Sugiura T, Kishimoto S, Oka S, Gokoh M, (2006). Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 45: 405-446.
64. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, et al,. (2007). Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 152: 734-743. (Pubitemid 350034991)
65. Van der Stelt M, Di Marzo V, (2005). Cannabinoid receptors and their role in neuroprotection. NeuroMol Med 7: 37-50. (Pubitemid 41278188)
66. Waksman Y, Olson JM, Carlisle SJ, Cabral GA, (1999). The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288: 1357-1366. (Pubitemid 29254178)
67. Walker D, Lue L-F, (2007). Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr Neuropharmacol 5: 232-243. (Pubitemid 350268184)
68. Walter L, Stella N, (2004). Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785. (Pubitemid 38446178)
69. Yang H, Chen C, (2008). COX-2 in synaptic signaling. Curr Pharm Des 14: 1443-1451.
70. Yang H, Zhang J, Andreasson K, Chen C, (2008). COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Mol Cell Neurosci 37: 682-695.
71. Zhang J, Chen C, (2008). Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 283: 22601-22611.